NATIONAL COMPREHENSIVE CANCER NETWORK

§ Category 1: Based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate. 4... References: 1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. Supplementary appendix available at: https://www.nejm.org/doi/full/10.1056/nejmoa1110557. 3. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed June 23, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no..

Also known as: National Comprehensive Cancer Network, Inc, NCCN